mRNA Synthesis Raw Materials Industry
The global mRNA synthesis raw materials market was valued at USD 1.72 billion in 2023, with a projected compound annual growth rate (CAGR) of 2.85% from 2024 to 2030. mRNA synthesis occurs through the process of transcription within the nucleus, using a DNA nucleotide sequence as a template. This process involves several stages, including initiation, elongation, editing, and termination. mRNA synthesis has broad applications in fields such as drug discovery, vaccine development, and therapeutic manufacturing. RNA-based vaccines, in particular, offer notable benefits including better immunogenicity, higher efficiency, and faster production times. These factors, along with growing academic and industrial interest in mRNA technology and increasing funding for research, are driving the market's growth.
A significant milestone in mRNA vaccine development occurred in March 2020, when the National Institute of Allergy & Infectious Diseases (NIAID) and Moderna, Inc. co-developed mRNA-1273, a vaccine with 94.1% efficacy in preventing symptomatic COVID-19. In December 2020, this vaccine received emergency use authorization from the U.S. Food & Drug Administration (FDA), leading to a dramatic increase in the use of mRNA vaccines during the pandemic. This surge in demand showcased the potential of mRNA technology, significantly boosting market growth.
In recent years, RNA research centers have been established at several prestigious institutions to explore the therapeutic potential of RNA, particularly in vitro transcribed (IVT) mRNA. Examples include the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, and the RNA Therapeutic Institute at the University of Massachusetts. Additionally, university spin-off companies, backed by substantial venture capital investments, have accelerated the preclinical and clinical development of mRNA-based therapeutics. Companies such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido have been at the forefront of these advancements. As academic and industrial interest in mRNA technology continues to grow, the demand for mRNA synthesis raw materials is expected to increase, further propelling market growth.
Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market
Type Insights
Capping Agents Segment Leading the Market (2023):
- In 2023, the capping agents segment held the largest revenue share of 39.17% in the global mRNA synthesis raw materials market.
- Capping and tailing are critical steps in producing active mRNA for functional studies, especially in eukaryotic cells where these processes help prevent mRNA degradation and enhance translation.
- Capping agents act as binding molecules or stabilizers, preventing steric hindrance or agglomeration during mRNA synthesis.
- The essential role of capping agents in ensuring the stability and functionality of mRNA is a key factor driving the growth of this segment.
Fastest CAGR for Capping Agents (2024-2030):
- The capping agents segment is expected to expand at the fastest compound annual growth rate (CAGR) of 3.26% over the forecast period from 2024 to 2030.
- This rapid growth is largely due to the development of modern alternatives to traditional enzymatic capping methods used in mRNA synthesis.
- Major market players are innovating new capping technologies to support the production of mRNA therapeutics and vaccines.
- For example, TriLink has developed CleanCap technology, which provides GMP-grade CleanCap reagents. These reagents enable the efficient development of 5' Cap1 mRNA with 95% efficiency, offering a quick and easy method for mRNA production.
- The continuous advancements in capping technologies are anticipated to further propel segment growth and drive the overall market.
Order a free sample PDF of the mRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
